HCM Hutchison China Meditech Ltd Sponsored ADR

Chi-Med to Announce 2019 Final Results

Chi-Med to Announce 2019 Final Results

LONDON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich Mean Time (GMT).

A presentation for analysts and investors will be held at 9:00 am GMT (5:00 pm Hong Kong Time) on the same day at Panmure Gordon, One New Change, London, EC4M 9AF, UK. The presentation will be webcast live via the company website at .  The presentation will be available to download before the analyst presentation begins.

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm GMT on the same day).  

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement.  A replay will also be available on the website shortly after each event.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products.  Its Innovation Platform, Hutchison MediPharma, has about 500 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world.  Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market.  For more information, please visit: -med.com.

CONTACTS

Investor Enquiries 
Mark Lee, Senior Vice President
Annie Cheng, Vice President+1 (973) 567 3786
David Dible, Citigate Dewe Rogerson 9 (Mobile)

Xuan Yang, Solebury Trout+1 (415) 971 9412 (Mobile)

  
Media Enquiries 
UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson 8 (Mobile)

Americas – Brad Miles, Solebury Trout+1 (917) 570 7340 (Mobile)

Hong Kong & Asia ex-China– Joseph Chi Lo, Brunswick (Mobile)

 – Zhou Yi, Brunswick (Mobile)

Mainland China – Sam Shen, Edelman 29 (Mobile)

  
Nominated Advisor 
Atholl Tweedie, Panmure Gordon (UK) Limited+44 (20) 7886 2500

 

EN
31/01/2020

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

China Healthcare: Entering a new phase of accelerated growth. Upgrade ...

China's biotechnology sector has entered an accelerated growth phase, with firms expanding their innovative commercial product portfolios, achieving significant outlicensing deals and enjoying unexpected profitability. With an unprecedented showing of 74 oral presentations at ASCO 2025, the sector highlighted its robust pipeline and expanding role in global innovation. Sustained policy support and globalisation efforts will further support this expansion. Upgrade to OVERWEIGHT with Innovent, Han...

Franc Gregori ... (+3)
  • Franc Gregori
  • Lala Gregorek
  • Philippa Gardner

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: The highly positive data from the China Phase III SACHI study of savolitinib, with statistically significant PFS benefits and clinically meaningful improvements for 2L EGFRm NSCLC with MET amplification patients, reassure on the upcoming approval decision in China, and help to de-risk the ongoing Phase III SAFFRON study for global approvals, in our view. MET amplification, which is estimated to affect c 35% of 2L patients following 3rd gen EGFR treatment, leads to a poorer pr...

 PRESS RELEASE

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fru...

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one t...

 PRESS RELEASE

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 A...

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting — The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the data presented — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM:​HCM; HKEX:​13) announces primary results from the interim analysis of the SACHI Phase III study. These results...

Franc Gregori ... (+3)
  • Franc Gregori
  • Lala Gregorek
  • Philippa Gardner

HUTCHMED: Looking ahead to the next chapter

HUTCHMED’s pipeline should deliver several catalysts over the next 12-24 months as the seven programmes currently in 14 registration/registration-intent trials yield potential near- to mid- term regulatory filings. Imminent detailed savolitinib data at ASCO could help de-risk ex-China opportunities, whilst potential China launch in the EGFR TKI refractory setting should aid revenue growth. The novel ATTC platform is a potentially significant new opportunity with further disclosures anticipated b...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch